Treatment Strategy after Noncurative Endoscopic Resection for Early Gastric Cancers in Patients Aged ≥ 85 Years: a Multicenter Retrospective Study in a Highly Aged Area of Japan.
Hatta Waku,Toya Yosuke,Shimada Tomohiro,Hamada Koichi,Watanabe Ko,Nakamura Jun,Fukushi Daisuke,Koike Tomoyuki,Shinkai Hirohiko,Ito Hirotaka,Matsuhashi Tamotsu,Fujimori Shusei,Iwai Wataru,Hanabata Norihiro,Shiroki Takeharu,Sasaki Yu,Fujishima Yuukou,Tsuji Tsuyotoshi,Yorozu Haruka,Yoshimura Tetsuro,Horikawa Yohei,Takahashi Yasushi,Takahashi Hiroshi,Kondo Yutaka,Fujiwara Takao,Mizugai Hisata,Gonai Takahiro,Tatsuta Tetsuya,Onochi Kengo,Kudara Norihiko,Abe Keinosuke,Ogata Yohei,Ohira Tetsuya,Horikawa Yoshinori,Ishihata Ryoichi,Hikichi Takuto,Satoh Kennichi,Iijima Katsunori,Fukuda Shinsaku,Matsumoto Takayuki,Masamune Atsushi
DOI: https://doi.org/10.1007/s00535-022-01948-7
2023-01-01
Journal of Gastroenterology
Abstract:The guidelines recommend additional gastrectomy after noncurative endoscopic resection for early gastric cancers (EGCs). However, no additional treatment might be acceptable in some patients aged ≥ 85 years. We aimed to identify this patient group using the data in a highly aged area. We enrolled patients aged ≥ 85 years after noncurative endoscopic resection for EGCs at 30 institutions of the Tohoku district in Japan between 2002 and 2017. Treatment selection and prognosis after noncurative endoscopic resection were investigated. Fourteen candidates were evaluated using the Cox model to identify risk factors for poor overall survival (OS) in patients with no additional treatment. Of 1065 patients aged ≥ 85 years, 143 underwent noncurative endoscopic resection. Despite the guidelines’ recommendation, 88.8% of them underwent no additional treatment. The 5-year OS rates in those with additional gastrectomy and those with no additional treatment were 63.1 and 65.2%, respectively. Multivariate analysis showed independent risk factors for poor OS in patients with no additional treatment were the high-risk category in the eCura system (hazard ratio [HR], 2.91), Charlson comorbidity index (CCI) ≥ 3 (HR, 2.78), and male (HR, 2.04). In patients with no additional treatment, nongastric cancer-specific survival was low (69.0% in 5 years), whereas disease-specific survival rates were very high in the low- and intermediate-risk categories of the eCura system (100.0 and 97.1%, respectively, in 5 years). No additional treatment may be acceptable in the low- and intermediate-risk categories of the eCura system in patients aged ≥ 85 years with noncurative endoscopic resection for EGCs.